α-Synuclein Pathology in Synucleinopathies: Mechanisms, Biomarkers, and Therapeutic Challenges., PMID:40508212
Generation of iPSC lines with tagged α-synuclein for visualization of endogenous protein in human cellular models of neurodegenerative disorders., PMID:40456614
Hippocampal subfields: volume, neuropathological vulnerability and cognitive decline in Alzheimer's and Parkinson's disease., PMID:40448161
Multiplex Immunofluorescent Analysis of Alpha-Synuclein in Nigral Lewy Bodies With Heat-Induced Antibody Stripping Reveals an Intricate Multilayered Structure., PMID:40442873
Nanoplatforms Targeting Intrinsically Disordered Protein Aggregation for Translational Neuroscience Applications., PMID:40423094
Rational selection of the monoclonal α-synuclein antibody amlenetug (Lu AF82422) for the treatment of α-synucleinopathies., PMID:40404755
Fluid biomarkers in atypical Parkinsonism: current state and future perspectives., PMID:40392273
Electro-Sensing Analysis for Parkinson's Disease Biomarker on Dual-Electrode Surface: Complemented by Molecular Docking., PMID:40384391
Nanomaterial Enhances the Performance of Amyloid-beta Biosensing for Alzheimer's Disease Diagnosis., PMID:40337966
Targeted proteomic biomarker profiling using NULISA in a cohort enriched with risk for Alzheimer's disease and related dementias., PMID:40318118
Abundant non-inclusion α-synuclein pathology in Lewy body-negative LRRK2-mutant cases., PMID:40314782
Facile generation of drug-like conformational antibodies specific for amyloid fibrils., PMID:40301692
Interactions of Therapeutic Antibodies With Presynaptically-Released Misfolded Proteins in Neurodegenerative Diseases. A Spatial Monte-Carlo Simulation Study., PMID:40296445
Hypothermia Shifts Neurodegeneration Phenotype in Neonatal Human Hypoxic-Ischemic Encephalopathy but Not in Related Piglet Models: Possible Relationship to Toxic Conformer and Intrinsically Disordered Prion-like Protein Accumulation., PMID:40277911
Evaluation of 6 monoclonal antibodies against Ser129-phosphorylated α-synuclein: Critical role of proteinase K antigen retrieval and superior sensitivity of the D1R1R clone in human skin biopsies., PMID:40261899
PET tracer development for imaging α-synucleinopathies., PMID:40227383
Fibril fuzzy coat is important for α-synuclein pathological transmission activity., PMID:40215967
A fragment of Calpain-1 cleaved α-Synuclein quantified in serum is upregulated in patients with Parkinson's disease., PMID:40204767
Proximity proteomics reveals unique and shared pathological features between multiple system atrophy and Parkinson's disease., PMID:40122840
HC070, a Transient Receptor Potential Canonical 5 (TRPC5) Channels Inhibitor Ameliorated α-synuclein Preformed Fibrils-Induced Parkinson's Disease: A Neurobehavioural and Mechanistic Study., PMID:40066713
Overlapping presence of β-amyloid, tau, p-tau, and α-synuclein in skin nerve fibers in Alzheimer's disease., PMID:40042672
Autoantibodies against α-synuclein inhibit its aggregation and cytotoxicity., PMID:40037001
Cell-Division-Independent Rapid Expression of DNA Delivered with α-Synuclein-Gold Nanoparticle Conjugates., PMID:40014054
Targeted Raman Visualization and Mitigation of α-Synuclein Amyloidogenesis in Living Zebrafish by a Nanobody-Decorated Polydiacetylene., PMID:39996265
Prasinezumab slows motor progression in Parkinsons disease: beyond the clinical data., PMID:39971932
Multimer Detection System: A Universal Assay System for Differentiating Protein Oligomers from Monomers., PMID:39940966
Proteolytic therapeutic modalities for amyloidoses: Insights into immunotherapy, PROTAC, and photo-oxygenation., PMID:39939242
Altered ATP13A2/PARK9 Levels Influence α-Synuclein Accumulation in Neurons via Phagocytosis and Secretion in Glial Cells., PMID:39936955
An autopsy case of coexisting spinal and bulbar muscular atrophy and multiple system atrophy., PMID:39916440
The roles of functional bacterial amyloids in neurological physiology and pathophysiology: Pros and cons for neurodegeneration., PMID:39909290
Neuronal α-synuclein toxicity is the key driver of neurodegeneration in multiple system atrophy., PMID:39908177
Retraction Notice to: ESCRT-mediated Uptake and Degradation of Brain-targeted α-synuclein Single Chain Antibody Attenuates Neuronal Degeneration In Vivo., PMID:39900036
Quantification of cinpanemab (BIIB054) binding to α-synuclein in cerebrospinal fluid of phase 1 single ascending dose samples., PMID:39892989
Biomarker treatment effects in two phase 3 trials of gantenerumab., PMID:39887500
Tracing TMEM106B fibril deposition in aging and Parkinson's disease with dementia brains., PMID:39872397
Correction to α-synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease., PMID:39869484
Distinct subcellular localization of tau and alpha-synuclein in lewy body disease., PMID:39838428
Multi-Targeting Macrocyclic Peptides as Nanomolar Inhibitors of Self- and Cross-Seeded Amyloid Self-Assembly of α-Synuclein., PMID:39822034
Retraction Notice to "Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy" [Neurobiology of Disease 104 (2017) 85-96]., PMID:39818529
Nuclear Alpha-Synuclein in Parkinson's Disease and the Malignant Transformation in Melanoma., PMID:39816956
A nanoparticle-based wireless deep brain stimulation system that reverses Parkinson's disease., PMID:39813330
The interaction of tPA with NMDAR1 drives neuroinflammation and neurodegeneration in α-synuclein-mediated neurotoxicity., PMID:39810216
Neuronal LAG3 facilitates pathogenic α-synuclein neuron-to-neuron propagation., PMID:39803449
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data., PMID:39798255
Artificial Intelligence-Based Methodologies for Early Diagnostic Precision and Personalized Therapeutic Strategies in Neuro-Ophthalmic and Neurodegenerative Pathologies., PMID:39766465
N-terminus α-synuclein detection reveals new and more diverse aggregate morphologies in multiple system atrophy and Parkinson's disease., PMID:39726015
Co-pathologies modify hippocampal protein accumulation patterns in neurodegenerative diseases., PMID:39711489
A brain-penetrant bispecific antibody lowers oligomeric alpha-synuclein and activates microglia in a mouse model of alpha-synuclein pathology., PMID:39676023
An update on immune-based alpha-synuclein trials in Parkinson's disease., PMID:39666171
What is the future for dementia with Lewy bodies?, PMID:39666092
For research use only. Not for human or drug use.
